Gilead to Acquire Ouro Medicines to Advance OM336 Autoimmune T Cell Engager, Eyes Galapagos Collaboration
Gilead Sciences will acquire Ouro Medicines for $1.675 billion upfront plus up to $500 million in milestones to add OM336, a BCMAxCD3 T cell engager, to its inflammation portfolio. OM336 has shown single‑cycle efficacy in autoimmune diseases such as AIHA and ITP and holds Fast Track and Orphan Drug designations with registrational studies expected in 2027. Gilead is also pursuing a strategic collaboration with Galapagos on Ouro assets, with Galapagos covering half of upfront and milestone payments, sharing development costs, and receiving 20%–23% royalties on net sales while Gilead retains worldwide commercialization rights (except Greater China). The deal aims to advance immune-reset therapies by depleting pathogenic B cells/plasma cells to reduce inflammation, potentially enabling durable drug‑free remission; regulatory and integration risks remain.
